) The Ovarian Pathology Facility at MDACC provides basic science and clinical investigators with human tissue for research projects from patients treated at M.D. Anderson for ovarian cancer. The core's functions include tissue collection and processing, tissue storage, histopathologic review, specimen database management, and distribution of well-characterized specimens to project investigators. The main goal of SPORE is to provide adequate materials and services in support of the research projects included in the SPORE proposal; however, materials will be made available to SPORE investigators at other institutions whenever possible and to investigators outside the SPORE projects.
The specific aims of the proposals are (1) to provide technical services and pathologic review of all clinical specimens used in the clinical and research projects outlined in the SPORE proposal, (2) to maintain a tissue repository of ovarian cancer specimens, (3) to retrieve paraffin-embedded tissue from M.D. Anderson archives and formalin-fixed and paraffin-embedded tissue from referring institutions and (4) to maintain an on-line computerized database of pertinent data on each specimen and the patient from whom it was taken. Data and specimens will be made available to investigators at other SPORE sites. The core's computerized database contains data on specimen type, location, and clinical and pathologic findings for each specimen. Patient confidentiality is maintained by password protection.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA083639-03S1
Application #
6593062
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-09-28
Project End
2002-08-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Rhyasen, Garrett W; Yao, Yi; Zhang, Jingwen et al. (2018) BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS One 13:e0200826
Chen, Jian; Zaidi, Sobia; Rao, Shuyun et al. (2018) Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-? Pathway. Gastroenterology 154:195-210
Sun, Chaoyang; Yin, Jun; Fang, Yong et al. (2018) BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33:401-416.e8
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Jung, Youn-Sang; Wang, Wenqi; Jun, Sohee et al. (2018) Deregulation of CRAD-controlled cytoskeleton initiates mucinous colorectal cancer via ?-catenin. Nat Cell Biol 20:1303-1314
Jung, Youn-Sang; Jun, Sohee; Kim, Moon Jong et al. (2018) TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/?-catenin signalling. Nat Cell Biol 20:1421-1433
Nagaraja, Archana S; Dood, Robert L; Armaiz-Pena, Guillermo et al. (2018) Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 3:
Seo, Hyeonglim; Choi, Ikjang; Whiting, Nicholas et al. (2018) Hyperpolarized Porous Silicon Nanoparticles: Potential Theragnostic Material for 29 Si Magnetic Resonance Imaging. Chemphyschem 19:2143-2147
Mitamura, T; Pradeep, S; McGuire, M et al. (2018) Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene 37:722-731
Yuan, Jiao; Hu, Zhongyi; Mahal, Brandon A et al. (2018) Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 34:549-560.e9

Showing the most recent 10 out of 648 publications